Ann: GENERAL: PEB: Peer Reviewed Scientific Publi

• Release Date: 06/08/12 11:36
• Summary: GENERAL: PEB: Peer Reviewed Scientific Publication
• Price Sensitive: No
• Download Document  4.39KB

					

PEB
06/08/2012 09:36
GENERAL

REL: 0936 HRS Pacific Edge Limited

GENERAL: PEB: Peer Reviewed Scientific Publication

Peer reviewed scientific publication confirms efficacy of Cxbladder  test

The prestigious American Journal of Urology has published further evidence
that confirms the effectiveness of Pacific Edge's Cxbladder  test for
detecting bladder cancer.

The peer reviewed scientific paper has been published by the Journal online
ahead of publication in the September print edition, which circulates to an
estimated 18,000 members of the American Urological Association and other
urologists around the world.

Specifically the paper, "A Multigene Urine Test for the Detection and
Stratification of Bladder Cancer in Patients Presenting with Hematuria"
(O'Sullivan et al)* found that the simple-to-use, non-invasive Cxbladder
test has the ability to detect nearly all tumours of concern to urologists.

The findings in the paper, written by scientific and medical specialists, are
based on an international, multicentre clinical study involving 485 patients
in Australasia who presented with hematuria (blood in urine - an indication
of possible bladder cancer).

The research team analysed the results of initial testing undertaken by
cystoscopy (physical inspection of the urinary tract and bladder), cytology
(urine analysis), uRNA (a forerunner of Cxbladder ) and NMP22 . The results
cited in the scientific publication compare Cxbladder  with these other
commonly used bladder cancer detection tests.

Follow-up tests, 12 months later, on patients who had tested negative as a
result of the benchmark cystoscopy inspection but positive by Cxbladder  also
revealed that three of the patients had tumours, two of which were in an
advanced state and likely to have been present for some time. This ability of
Cxbladder  to identify these individuals provides a strong back up for
clinicians.

The paper concludes that the performance of Cxbladder  challenges the current
clinical practice of the use of cytology as the routine adjunct to cystoscopy
and that Cxbladder  can be used to prioritise primary care patients for
cystoscopy.

Pacific Edge's Chief Executive Officer David Darling says publication of a
peer-reviewed scientific research paper in the Journal of Urology confirming
the performance of Cxbladder  is a significant milestone for the acceptance
of Cxbladder  by clinicians globally.

"The United States, the largest healthcare market in the world, is the most
important market for Pacific Edge in its global roll-out of Cxbladder . The
Journal Of Urology is widely read by urologists, medical insurers and often
those bladder cancer patients who are looking for an accurate, more
convenient and less intrusive method of detecting bladder cancer. "

Cxbladder  will be formally launched in the USA early next year following
CLIA (Clinical Laboratory Improvements Amendment) certification of the
purpose built testing laboratory now being completed by Pacific Edge
Diagnostics USA in Hershey, Pennsylvania.

"Cxbladder  turns 10 years of research and development into an accurate
easy-to-use urine test that will transform bladder cancer detection by
clinicians and ease the discomfort of thousands of people who present to
their doctors with hematuria."

Cxbladder  is attracting keen interest amongst general practitioners, GP's,
in New Zealand and Australia following attendance at specialist conventions
and regional medical conferences in Australia and New Zealand by both Pacific
Edge and its Australian licensee, Healthscope. These conferences have
increased the overall awareness of the test to both clinicians and
physicians.

"Clinicians and physicians have been quick to recognise that this is an
accurate test that they can use in their clinical routine to detect bladder
cancer in patients. This will also enable these patients to be prioritised
for specialist treatment by their urologist."

* An abstract of the article can be found on the Journal of Urology's website
at:

http://www.jurology.com/article/S0022-5347(12)03701-9/abstract

For further information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
+64 (3) 479 5800

Editor's note:
Pacific Edge is a leading molecular cancer diagnostics company based in
Dunedin with a portfolio of patents for cancer diagnostic and prognostic
tools. Pacific Edge's shares are listed on the NZX under the ticker code PEB.
End CA:00225661 For:PEB    Type:GENERAL    Time:2012-08-06 09:36:36